<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>β-TrCP1 inhibitor &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/%ce%b2-trcp1-inhibitor/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 26 Nov 2025 13:59:12 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>β-TrCP1 inhibitor &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Targeting β-TrCP1: Breakthrough in Anti-Inflammatory Therapy</title>
		<link>https://bioengineer.org/targeting-%ce%b2-trcp1-breakthrough-in-anti-inflammatory-therapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 26 Nov 2025 13:58:49 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[anti-inflammatory therapy]]></category>
		<category><![CDATA[chronic disease treatment]]></category>
		<category><![CDATA[Chronic inflammation treatment]]></category>
		<category><![CDATA[NRF2 stabilization]]></category>
		<category><![CDATA[Oxidative stress modulation]]></category>
		<category><![CDATA[Protein-protein interaction inhibition]]></category>
		<category><![CDATA[Small-molecule therapeutics]]></category>
		<category><![CDATA[β-TrCP1 inhibitor]]></category>
		<guid isPermaLink="false">https://bioengineer.org/targeting-%ce%b2-trcp1-breakthrough-in-anti-inflammatory-therapy/</guid>

					<description><![CDATA[Recent advancements in the field of anti-inflammatory therapy have showcased a potential breakthrough in the fight against chronic inflammatory diseases. A research team led by García-Yagüe and colleagues has proposed a novel inhibitor targeting the interaction between β-TrCP1 and NRF2, a mechanism that may transform therapeutic strategies for various inflammation-related disorders. Chronic inflammation is known [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">301630</post-id>	</item>
	</channel>
</rss>
